NASDAQ:RSLS - EnteroMedics Stock Price, Price Target & More

$0.60 -0.04 (-6.25 %)
(As of 04/23/2018 03:18 PM ET)
Previous Close$0.64
Today's Range$0.60 - $0.65
52-Week Range$0.58 - $6.45
Volume151,506 shs
Average Volume219,721 shs
Market Capitalization$20.94 million
P/E Ratio-0.19
Dividend YieldN/A
Beta2.52

About EnteroMedics (NASDAQ:RSLS)

EnteroMedics logoReShape Lifesciences Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses. The company develops the vBloc System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. It has collaboration with Mayo Clinic. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.

Receive RSLS News and Ratings via Email

Sign-up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:RSLS
CUSIP29365M20
Phone949-429-6680

Debt

Debt-to-Equity RatioN/A
Current Ratio1.98%
Quick Ratio1.58%

Price-To-Earnings

Trailing P/E Ratio-0.19
Forward P/E Ratio-1.18
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.29 million
Price / Sales15.33
Cash FlowN/A
Price / CashN/A
Book Value$2.55 per share
Price / Book0.24

Profitability

EPS (Most Recent Fiscal Year)($3.18)
Net Income$-33,810,000.00
Net Margins-2,627.66%
Return on Equity-78.84%
Return on Assets-69.45%

Miscellaneous

Employees83
Outstanding Shares32,950,000

How to Become a New Pot Stock Millionaire

EnteroMedics (NASDAQ:RSLS) Frequently Asked Questions

What is EnteroMedics' stock symbol?

EnteroMedics trades on the NASDAQ under the ticker symbol "RSLS."

When did EnteroMedics' stock split? How did EnteroMedics' stock split work?

Shares of EnteroMedics reverse split on the morning of Friday, January 8th 2016. The 1-15 reverse split was announced on Wednesday, December 23rd 2015. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 7th 2016. An investor that had 100 shares of EnteroMedics stock prior to the reverse split would have 7 shares after the split.

How were EnteroMedics' earnings last quarter?

EnteroMedics (NASDAQ:RSLS) posted its earnings results on Tuesday, November, 14th. The medical device company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.77. The medical device company had revenue of $0.36 million for the quarter. EnteroMedics had a negative return on equity of 78.84% and a negative net margin of 2,627.66%. View EnteroMedics' Earnings History.

When is EnteroMedics' next earnings date?

EnteroMedics is scheduled to release their next quarterly earnings announcement on Tuesday, May, 15th 2018. View Earnings Estimates for EnteroMedics.

What price target have analysts set for RSLS?

1 equities research analysts have issued 12 month target prices for EnteroMedics' shares. Their predictions range from $11.00 to $11.00. On average, they anticipate EnteroMedics' share price to reach $11.00 in the next year. View Analyst Ratings for EnteroMedics.

Who are some of EnteroMedics' key competitors?

Who are EnteroMedics' key executives?

EnteroMedics' management team includes the folowing people:
  • Mr. Dan W. Gladney, Chairman, Chief Exec. Officer and Pres (Age 65)
  • Dr. Mark B. Knudson Ph.D., Co-Founder and Special Advisor to the CEO (Age 69)
  • Mr. Scott P. Youngstrom, Sr. VP of Fin. & CFO (Age 58)
  • Mr. Naqeeb A. Ansari, VP of International Sales & US Veterans Admin. Hospitals (Age 57)
  • Mr. Jon T. Tremmel, Consultant to the CEO & Director (Age 72)

Has EnteroMedics been receiving favorable news coverage?

Media coverage about RSLS stock has trended somewhat positive this week, according to Accern Sentiment. The research firm rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. EnteroMedics earned a media sentiment score of 0.16 on Accern's scale. They also gave headlines about the medical device company an impact score of 44.54 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of EnteroMedics?

Shares of RSLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is EnteroMedics' stock price today?

One share of RSLS stock can currently be purchased for approximately $0.60.

How big of a company is EnteroMedics?

EnteroMedics has a market capitalization of $20.94 million and generates $1.29 million in revenue each year. The medical device company earns $-33,810,000.00 in net income (profit) each year or ($3.18) on an earnings per share basis. EnteroMedics employs 83 workers across the globe.

How can I contact EnteroMedics?

EnteroMedics' mailing address is 1001 Calle Amanecer, San Clemente CA, 92673. The medical device company can be reached via phone at 949-429-6680 or via email at [email protected]


MarketBeat Community Rating for EnteroMedics (RSLS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  178 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  310
MarketBeat's community ratings are surveys of what our community members think about EnteroMedics and other stocks. Vote "Outperform" if you believe RSLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RSLS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

EnteroMedics (NASDAQ:RSLS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for EnteroMedics in the last 12 months. Their average twelve-month price target is $11.00, suggesting that the stock has a possible upside of 1,733.33%. The high price target for RSLS is $11.00 and the low price target for RSLS is $11.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.00$11.00$11.00$11.03
Price Target Upside: 1,733.33% upside117.82% upside117.82% upside118.42% upside

EnteroMedics (NASDAQ:RSLS) Consensus Price Target History

Price Target History for EnteroMedics (NASDAQ:RSLS)

EnteroMedics (NASDAQ:RSLS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Ladenburg ThalmannReiterated RatingBuy$11.00LowView Rating Details
1/9/2017S&P Equity ResearchLower Price Target$17.19 -> $11.06N/AView Rating Details
6/9/2016Roth CapitalDowngradeBuy -> Neutral$3.00 -> $3.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

EnteroMedics (NASDAQ:RSLS) Earnings History and Estimates Chart

Earnings by Quarter for EnteroMedics (NASDAQ:RSLS)

EnteroMedics (NASDAQ:RSLS) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.51 EPS
Next Year EPS Consensus Estimate: $-0.27 EPS

EnteroMedics (NASDAQ RSLS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2018        
11/14/2017Q3($0.29)($1.06)$0.36 millionViewN/AView Earnings Details
8/8/2017Q2 2017($1.00)($0.91)$0.20 million$0.09 millionViewListenView Earnings Details
5/16/2017Q1 2017($0.63)($1.27)$0.04 millionViewN/AView Earnings Details
3/7/2017Q4 2016($0.44)($2.65)$0.14 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.50)($0.17)$0.34 million$0.30 millionViewN/AView Earnings Details
8/4/2016Q216($0.75)($0.49)$0.19 million$0.28 millionViewN/AView Earnings Details
5/5/2016Q1 2016($55.94)($57.34)$0.14 million$0.07 millionViewN/AView Earnings Details
2/17/2016Q315($0.90)($0.95)$0.43 million$0.15 millionViewListenView Earnings Details
11/9/2015Q3 2015($83.87)($41.94)$0.17 million$0.06 millionViewN/AView Earnings Details
8/6/2015Q215($0.10)($0.10)$0.06 million$0.08 millionViewN/AView Earnings Details
4/30/2015Q1 2015($94.36)($83.87)ViewN/AView Earnings Details
2/18/2015Q414($0.10)($0.09)ViewN/AView Earnings Details
11/12/2014Q3 14($0.10)($0.08)ViewN/AView Earnings Details
8/7/2014Q2($0.10)($0.11)ViewListenView Earnings Details
4/30/2014Q1 14($0.10)($0.10)ViewN/AView Earnings Details
2/12/2014Q413($0.10)($0.11)ViewN/AView Earnings Details
10/31/2013Q313($0.11)($0.11)ViewN/AView Earnings Details
7/31/2013Q2 2013($0.13)($0.11)ViewN/AView Earnings Details
5/1/2013Q1 2013($0.13)($0.14)$0.10 millionViewN/AView Earnings Details
2/13/2013Q4 2012($0.14)($0.17)$0.36 millionViewN/AView Earnings Details
10/24/2012Q3 2012($136.30)($146.78)ViewN/AView Earnings Details
8/7/2012Q2 2012($157.26)($134.20)ViewN/AView Earnings Details
4/24/2012Q1 2012($188.72)($160.41)ViewN/AView Earnings Details
1/26/2012Q4 2011($220.17)($229.61)ViewN/AView Earnings Details
10/20/2011Q3 2011($283.08)($271.54)ViewN/AView Earnings Details
7/21/2011Q2 2011($251.62)($208.64)ViewN/AView Earnings Details
1/27/2011Q4 2010($314.53)($361.71)ViewN/AView Earnings Details
10/21/2010Q3 2010($492.76)($614.38)ViewN/AView Earnings Details
7/22/2010Q2 2010($597.60)ViewN/AView Earnings Details
4/21/2010Q1 2010($440.25)($691.82)ViewN/AView Earnings Details
1/28/2010Q4 2009($1,320.75)($503.14)ViewN/AView Earnings Details
10/23/2009Q3 2009($1,383.65)($2,509.43)ViewN/AView Earnings Details
7/23/2009Q2 2009($1,383.65)($1,477.99)ViewN/AView Earnings Details
4/23/2009Q1 2009($1,257.86)($1,893.08)ViewN/AView Earnings Details
1/29/2009Q4 2008($2,830.19)($2,911.95)ViewN/AView Earnings Details
10/21/2008Q3 2008($3,773.58)($3,811.32)ViewN/AView Earnings Details
7/24/2008Q2 2008($3,584.90)($4,245.28)ViewN/AView Earnings Details
2/20/2008Q4 2007($3,081.76)($6,943.39)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

EnteroMedics (NASDAQ:RSLS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

EnteroMedics (NASDAQ RSLS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 26.40%
Institutional Ownership Percentage: 18.93%
Insider Trading History for EnteroMedics (NASDAQ:RSLS)

EnteroMedics (NASDAQ RSLS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/25/2017Carl GoldfischerDirectorSell4,668$4.85$22,639.80View SEC Filing  
6/3/2016Peter M DelangeSVPBuy20,000$0.55$11,000.0027,373View SEC Filing  
8/13/2015Mark B KnudsonCEOBuy303,000$0.25$75,750.00View SEC Filing  
6/19/2014Cathy FriedmanDirectorBuy11,800$1.70$20,060.00View SEC Filing  
1/8/2014Luke EvninDirectorSell556,585$2.50$1,391,462.50View SEC Filing  
2/27/2013Anthony P JanszDirectorBuy150,000$0.95$142,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

EnteroMedics (NASDAQ RSLS) News Headlines

Source:
DateHeadline
Free Post Earnings Research Report: Senseonics Quarterly Revenues Zoomed 867%Free Post Earnings Research Report: Senseonics' Quarterly Revenues Zoomed 867%
finance.yahoo.com - April 20 at 8:25 AM
Contrasting EnteroMedics (RSLS) and Vision Sciences (CGNT)Contrasting EnteroMedics (RSLS) and Vision Sciences (CGNT)
www.americanbankingnews.com - April 19 at 1:36 AM
Forty Surgeons Trained on ReShape Balloon at Hands-On Course During SAGES 2018Forty Surgeons Trained on ReShape Balloon at Hands-On Course During SAGES 2018
finance.yahoo.com - April 18 at 5:44 PM
ReShape Lifesciences Pioneers New Bio-electronic Technology for Treatment of Type 2 DiabetesReShape Lifesciences Pioneers New Bio-electronic Technology for Treatment of Type 2 Diabetes
finance.yahoo.com - April 10 at 5:29 PM
EnteroMedics (RSLS) Cut to "Strong Sell" at ValuEngineEnteroMedics (RSLS) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - April 8 at 12:54 PM
ReShape Lifesciences Continues Expansion in Middle East with Approval of ReShape Balloon in Saudi ArabiaReShape Lifesciences Continues Expansion in Middle East with Approval of ReShape Balloon in Saudi Arabia
finance.yahoo.com - April 3 at 5:34 PM
ReShape Lifesciences, Inc. to Host Earnings CallReShape Lifesciences, Inc. to Host Earnings Call
finance.yahoo.com - April 2 at 5:27 PM
ReShape Lifesciences Announces Fourth Quarter and Year End 2017 Financial ResultsReShape Lifesciences Announces Fourth Quarter and Year End 2017 Financial Results
finance.yahoo.com - April 2 at 5:27 PM
ReShape Lifesciences Announces $6 Million Registered Direct OfferingReShape Lifesciences Announces $6 Million Registered Direct Offering
finance.yahoo.com - April 2 at 8:41 AM
EnteroMedics (RSLS) Cut to "Hold" at Zacks Investment ResearchEnteroMedics (RSLS) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 30 at 1:07 PM
Reshape Lifesciences (RSLS) Rating Increased to Buy at Zacks Investment ResearchReshape Lifesciences (RSLS) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 29 at 11:24 AM
Reshape Lifesciences (RSLS) Scheduled to Post Earnings on MondayReshape Lifesciences (RSLS) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - March 26 at 2:04 AM
ReShape Lifesciences Announces Update on Integration Efforts and Reschedules Fourth Quarter and Full Year 2017 Conference Call to April 2, 2018ReShape Lifesciences Announces Update on Integration Efforts and Reschedules Fourth Quarter and Full Year 2017 Conference Call to April 2, 2018
finance.yahoo.com - March 20 at 8:29 AM
Reshape Lifesciences (RSLS) Lowered to Hold at Zacks Investment ResearchReshape Lifesciences (RSLS) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 17 at 2:56 PM
Reshape Lifesciences (RSLS) Stock Rating Upgraded by Zacks Investment ResearchReshape Lifesciences (RSLS) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 16 at 12:52 PM
ReShape vBloc to be Featured at the Bariatric Metabolic Surgery Standardization World Consensus Meeting - PR Newswire (press release)ReShape vBloc to be Featured at the Bariatric Metabolic Surgery Standardization World Consensus Meeting - PR Newswire (press release)
www.prnewswire.com - March 16 at 8:21 AM
ReShape vBloc to be Featured at the Bariatric Metabolic Surgery Standardization World Consensus MeetingReShape vBloc to be Featured at the Bariatric Metabolic Surgery Standardization World Consensus Meeting
finance.yahoo.com - March 16 at 8:21 AM
Reshape Lifesciences (RSLS) Set to Announce Earnings on ThursdayReshape Lifesciences (RSLS) Set to Announce Earnings on Thursday
www.americanbankingnews.com - March 15 at 1:38 AM
Critical Analysis: Reshape Lifesciences (RSLS) & Presbia (LENS)Critical Analysis: Reshape Lifesciences (RSLS) & Presbia (LENS)
www.americanbankingnews.com - March 9 at 3:16 AM
ReShape Lifesciences to Host Fourth Quarter and Full Year 2017 Conference Call on March 22, 2018 - PR Newswire (press release)ReShape Lifesciences to Host Fourth Quarter and Full Year 2017 Conference Call on March 22, 2018 - PR Newswire (press release)
www.prnewswire.com - March 8 at 8:24 AM
ReShape Lifesciences to Host Fourth Quarter and Full Year 2017 Conference Call on March 22, 2018ReShape Lifesciences to Host Fourth Quarter and Full Year 2017 Conference Call on March 22, 2018
finance.yahoo.com - March 8 at 8:24 AM
ReShape Lifesciences Announces Agreement with Academy Medical to Provide ReShape Balloon and ReShape ... - PR Newswire (press release)ReShape Lifesciences Announces Agreement with Academy Medical to Provide ReShape Balloon and ReShape ... - PR Newswire (press release)
www.prnewswire.com - March 7 at 8:19 AM
ReShape Lifesciences Announces Agreement with Academy Medical to Provide ReShape Balloon and ReShape vBloc to Department of Defense FacilitiesReShape Lifesciences Announces Agreement with Academy Medical to Provide ReShape Balloon and ReShape vBloc to Department of Defense Facilities
finance.yahoo.com - March 7 at 8:19 AM
ReShape LifeSciences (RSLS) Says Real-World Safety, Efficacy Study Results on ReShape Balloon Were PublishedReShape LifeSciences (RSLS) Says Real-World Safety, Efficacy Study Results on ReShape Balloon Were Published
www.streetinsider.com - March 6 at 5:40 PM
ReShape LifeSciences Announces Real-World Safety and Efficacy Study Results on ReShape Balloon™ Published in ... - PR Newswire (press release)ReShape LifeSciences Announces Real-World Safety and Efficacy Study Results on ReShape Balloon™ Published in ... - PR Newswire (press release)
www.prnewswire.com - March 5 at 8:18 AM
ReShape LifeSciences (RSLS) Says Real-World Safety, Efficacy Study Results on ReShape Balloon Were Published - StreetInsider.comReShape LifeSciences (RSLS) Says Real-World Safety, Efficacy Study Results on ReShape Balloon Were Published - StreetInsider.com
www.streetinsider.com - March 5 at 8:18 AM
ReShape LifeSciences Announces Real-World Safety and Efficacy Study Results on ReShape Balloon™ Published in Journal of Clinical Gastroenterology and HepatologyReShape LifeSciences Announces Real-World Safety and Efficacy Study Results on ReShape Balloon™ Published in Journal of Clinical Gastroenterology and Hepatology
finance.yahoo.com - March 5 at 8:18 AM
Contrasting Reshape Lifesciences (RSLS) & IRIDEX (IRIX)Contrasting Reshape Lifesciences (RSLS) & IRIDEX (IRIX)
www.americanbankingnews.com - February 26 at 1:22 PM
ReShape Lifesciences Technologies to be Featured at Minimally ... - PR Newswire (press release)ReShape Lifesciences Technologies to be Featured at Minimally ... - PR Newswire (press release)
www.prnewswire.com - February 23 at 8:23 AM
ReShape Lifesciences Technologies to be Featured at Minimally Invasive Surgery SymposiumReShape Lifesciences Technologies to be Featured at Minimally Invasive Surgery Symposium
finance.yahoo.com - February 22 at 5:37 PM
Reshape Lifesciences (RSLS) Raised to "Sell" at ValuEngineReshape Lifesciences (RSLS) Raised to "Sell" at ValuEngine
www.americanbankingnews.com - February 4 at 2:52 PM
ReShape Lifesciences Reports Preliminary Fourth Quarter and Full ... - PR Newswire (press release)ReShape Lifesciences Reports Preliminary Fourth Quarter and Full ... - PR Newswire (press release)
www.prnewswire.com - February 2 at 9:31 AM
ReShape Lifesciences Reports Preliminary Fourth Quarter and Full Year 2017 RevenueReShape Lifesciences Reports Preliminary Fourth Quarter and Full Year 2017 Revenue
finance.yahoo.com - February 1 at 9:40 AM
ReShape Lifesciences Announces 2017 Weight Loss Contest Winner - PR Newswire (press release)ReShape Lifesciences Announces 2017 Weight Loss Contest Winner - PR Newswire (press release)
www.prnewswire.com - January 27 at 3:46 PM
ReShape Lifesciences Announces 2017 Weight Loss Contest WinnerReShape Lifesciences Announces 2017 Weight Loss Contest Winner
finance.yahoo.com - January 25 at 9:37 AM
Reshape Lifesciences (RSLS) Lifted to Hold at Zacks Investment ResearchReshape Lifesciences (RSLS) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - January 17 at 12:42 PM
Reshape Lifesciences (RSLS) Raised to "Hold" at ValuEngineReshape Lifesciences (RSLS) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - January 1 at 12:04 PM
ReShape Lifesciences, Inc. :RSLS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017ReShape Lifesciences, Inc. :RSLS-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 28 at 5:20 PM
Analyzing ResMed (RMD) & Reshape Lifesciences (RSLS)Analyzing ResMed (RMD) & Reshape Lifesciences (RSLS)
www.americanbankingnews.com - December 28 at 1:13 PM
ReShape Lifesciences Announces Stocking Order from Medical Supplier in DubaiReShape Lifesciences Announces Stocking Order from Medical Supplier in Dubai
finance.yahoo.com - December 13 at 9:00 AM
EnteroMedics (RSLS) Lowered to Sell at Zacks Investment ResearchEnteroMedics (RSLS) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - December 6 at 6:02 AM
ReShape Lifesciences Announces Coverage of ReShape Dual Balloon by Major Telecom CompanyReShape Lifesciences Announces Coverage of ReShape Dual Balloon by Major Telecom Company
finance.yahoo.com - December 4 at 8:42 AM
Comparing EnteroMedics (RSLS) and Its PeersComparing EnteroMedics (RSLS) and Its Peers
www.americanbankingnews.com - December 3 at 11:10 PM
EnteroMedics (RSLS) Raised to "Hold" at ValuEngineEnteroMedics (RSLS) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - December 2 at 6:56 PM
Head-To-Head Analysis: EnteroMedics (RSLS) versus Its CompetitorsHead-To-Head Analysis: EnteroMedics (RSLS) versus Its Competitors
www.americanbankingnews.com - November 30 at 7:24 PM
Critical Contrast: EnteroMedics (RSLS) and The CompetitionCritical Contrast: EnteroMedics (RSLS) and The Competition
www.americanbankingnews.com - November 30 at 11:18 AM
Reviewing EnteroMedics (RSLS) and Its PeersReviewing EnteroMedics (RSLS) and Its Peers
www.americanbankingnews.com - November 25 at 9:18 PM
EnteroMedics (RSLS) vs. Its Competitors Head to Head AnalysisEnteroMedics (RSLS) vs. Its Competitors Head to Head Analysis
www.americanbankingnews.com - November 24 at 9:12 PM
EnteroMedics Inc. (RSLS) Downgraded by Zacks Investment Research to HoldEnteroMedics Inc. (RSLS) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - November 22 at 7:18 PM
Comparing EnteroMedics (RSLS) and Its RivalsComparing EnteroMedics (RSLS) and Its Rivals
www.americanbankingnews.com - November 22 at 1:22 PM

SEC Filings

EnteroMedics (NASDAQ:RSLS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

EnteroMedics (NASDAQ:RSLS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

EnteroMedics (NASDAQ RSLS) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.